Who are AGT4's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Edarbi, Cozaar, Placebo to Telmisartan, captopril, Losartan (drug), Valsartan (-based therapy) arm, VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/agt4.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AGT4 — Competitive Intelligence Brief

AGT4 (AGT4) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist. Area: Cardiovascular.

phase 3 Angiotensin II receptor antagonist AT1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

AGT4 (AGT4) — Ahn-Gook Pharmaceuticals Co.,Ltd. AGT4 is an angiotensin II receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AGT4 TARGET	AGT4	Ahn-Gook Pharmaceuticals Co.,Ltd	phase 3	Angiotensin II receptor antagonist	AT1 receptor
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Cozaar	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
Placebo to Telmisartan	Placebo to Telmisartan	Novartis	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
captopril, Losartan (drug)	captopril, Losartan (drug)	National Taiwan University Hospital	marketed	ACE inhibitor and angiotensin II receptor antagonist combination	ACE enzyme and AT1 receptor
Valsartan (-based therapy) arm	Valsartan (-based therapy) arm	Hippocration General Hospital	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE	VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE	Novartis	marketed	Angiotensin II receptor blocker (ARB) + thiazide diuretic	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (NCC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Edarbi · 9066936 · US
2030-02-04 — Edarbi · 9169238 · US
2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (Angiotensin II receptor antagonist class)

Abbott · 1 drug in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
Ain Shams University · 1 drug in this class
Boryung Pharmaceutical Co., Ltd · 1 drug in this class
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
EMS · 1 drug in this class
Kaohsiung Medical University Chung-Ho Memorial Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
St. Joseph's Hospital and Medical Center, Phoenix · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AGT4 — Competitive Intelligence Brief. https://druglandscape.com/ci/agt4. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab